Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,421.00+0.27%ETH$2,544.63+3.25%GOLD$4,391.40-0.36%OIL$100.62-1.81%
Smart Investors Daily
Aurinia Pharmaceuticals Inc. logo

NASDAQ · AUPH

Aurinia Pharmaceuticals Inc.

Healthcare · Biotechnology

$16.11

Up+$0.05 (+0.29%)

Updated Sep 11, 2026, 6:36 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.1B
P/E ratio
28.02
Dividend yield
0.00%
52-week range
$13.82 – $19.25
Volume
687.41K
Avg. volume
1.77M

Price performance

AUPH price history

1M range · 0 trading sessions · Daily adjusted prices

AUPH does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AUPH news

The latest Smart Investors Daily articles mentioning AUPH.

Stock researchCompany · Overview

AUPH research

Overview

Company profile and research snapshot.

Company profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.50
Implied upside
—
Analysts
—
AUPH recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalSector Perform—
Dec 3, 2025Leerink PartnersMarket Perform—
Nov 7, 2025JefferiesBuy—
Nov 5, 2025RBC CapitalSector Perform—
Aug 1, 2025RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By